InvestorsHub Logo
Followers 47
Posts 4199
Boards Moderated 1
Alias Born 03/02/2007

Re: None

Thursday, 07/21/2011 12:24:58 PM

Thursday, July 21, 2011 12:24:58 PM

Post# of 17
some DD:

NORH RM with http://www.fastrackpharma.com/ news yesterday moved from .05 to .50 so far.
1 for 10 small RS.
Small float after RM - 16,564,063

FasTrack Pharmaceuticals, Inc has agreement with APRI - NASDAQ company
"In March 2010, FasTrack sold the worldwide rights of PrevOnco to Apricus Biosciences, Inc. (“Apricus Bio”). Under the terms of the agreement, FasTrack and Apricus Bio will share equally in any future revenues from PrevOnco, including payments received from potential licensing partners"

Insiders owned more than 50% of the OS before RM. IMO, they went with this merger knowing that the share prize will rise to dollar(s) level once things evolves.

8k
"ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

(a) On July 13, 2011, we entered into a Merger Agreement and Plan of Merger ("Agreement")with FasTrack Pharmaceuticals, Inc., a Delaware corporation. FasTrack was organized in October 2008. FasTrack is engaged in the business of the development of innovative pharmaceutical products. The company has unique delivery platforms and know-how which provide a basis for the therapeutic drugs under development. The Agreement is attached as an exhibit to this Form 8-K. There is no material relationship between North Horizon and its affiliates and any of the other parties, other than the Agreement.

A brief summary of the terms and conditions of the Agreement follows. FasTrack will merge with a subsidiary of North Horizon whereby FasTrack will become a subsidiary of North Horizon. The shareholders, convertible note holder, and warrant holder of FasTrack will receive in the transaction the number of shares comprising ninety-two per cent (92%) of the fully-diluted shares of the Company as of the Closing which shares will shares will be issued after the reverse split. This summary incorporates by reference the complete Merger Agreement and Plan of Merger which is an Exhibit to this report.

Prior to the Closing North Horizon will amend its Articles of Incorporation to change its name and to increase its authorized capital to 150,000,000 shares of common stock, par value of $.001 per share and North Horizon shall adopt a recapitalization by a reverse stock split on the basis of ten shares into one share for the issued and outstanding shares North Horizon common stock. Pursuant to the terms of the Agreement the current directors will resign and appoint three new directors, Vivian Liu; Henry Esber, Ph.D.; and Ziad Mirza, M.D. The appointment of the new directors will become effective upon their acceptance and the closing. It is anticipated that our principal shareholder who owns approximately sixty-three per cent (63%) of the issued and outstanding shares of common stock will approve by written consent the foregoing proposals to amend the Company's Article of incorporation.

The closing will cause a change in control of the Company. There will be new officers and directors, and the present shareholders will become minor shareholders of the Company. Presently the Company has 13,251,250 shares of common stock issued and outstanding. The effect of the reverse split will be to reduce that number to 1,325,125. To acquire the shares of FasTrack the Company will issue to the FasTrack shareholders, convertible note holder, and warrant holder, on a fully-diluted basis, approximately 15,238,938 shares (post reverse split). When these shares are issued, the Company will then have outstanding approximately 16,564,063 shares of common stock."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.